U.S. Markets closed
  • S&P Futures

    3,658.00
    +34.75 (+0.96%)
     
  • Dow Futures

    29,897.00
    +268.00 (+0.90%)
     
  • Nasdaq Futures

    12,392.00
    +115.00 (+0.94%)
     
  • Russell 2000 Futures

    1,843.80
    +23.70 (+1.30%)
     
  • Crude Oil

    44.99
    -0.35 (-0.77%)
     
  • Gold

    1,788.30
    +7.40 (+0.42%)
     
  • Silver

    22.77
    +0.24 (+1.07%)
     
  • EUR/USD

    1.1963
    +0.0029 (+0.2393%)
     
  • 10-Yr Bond

    0.8440
    +0.0020 (+0.24%)
     
  • Vix

    20.57
    -0.27 (-1.30%)
     
  • GBP/USD

    1.3359
    +0.0028 (+0.2071%)
     
  • USD/JPY

    104.4290
    +0.1050 (+0.1007%)
     
  • BTC-USD

    19,526.03
    +16.15 (+0.08%)
     
  • CMC Crypto 200

    383.19
    +18.60 (+5.10%)
     
  • FTSE 100

    6,266.19
    -101.39 (-1.59%)
     
  • Nikkei 225

    26,824.46
    +390.84 (+1.48%)
     

Shareholders Of Cyclopharm (ASX:CYC) Must Be Happy With Their 293% Total Return

Simply Wall St
·3 min read

Cyclopharm Limited (ASX:CYC) shareholders have seen the share price descend 13% over the month. But that doesn't change the fact that the returns over the last five years have been very strong. We think most investors would be happy with the 269% return, over that period. Generally speaking the long term returns will give you a better idea of business quality than short periods can. Only time will tell if there is still too much optimism currently reflected in the share price.

View our latest analysis for Cyclopharm

Cyclopharm isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually expect strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

For the last half decade, Cyclopharm can boast revenue growth at a rate of 6.5% per year. That's a fairly respectable growth rate. Broadly speaking, this solid progress may well be reflected by the healthy share price gain of 30% per year over five years. It's well worth monitoring the growth trend in revenue, because if growth accelerates, that might signal an opportunity. Accelerating growth can be a sign of an inflection point - and could indicate profits lie ahead. Worth watching 100%

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

What About Dividends?

As well as measuring the share price return, investors should also consider the total shareholder return (TSR). Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. As it happens, Cyclopharm's TSR for the last 5 years was 293%, which exceeds the share price return mentioned earlier. The dividends paid by the company have thusly boosted the total shareholder return.

A Different Perspective

It's nice to see that Cyclopharm shareholders have received a total shareholder return of 76% over the last year. Of course, that includes the dividend. That gain is better than the annual TSR over five years, which is 31%. Therefore it seems like sentiment around the company has been positive lately. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. It's always interesting to track share price performance over the longer term. But to understand Cyclopharm better, we need to consider many other factors. For instance, we've identified 2 warning signs for Cyclopharm that you should be aware of.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.